Background: Prothrombin complex concentrate (PCC) is increasingly used to correct acquired coagulopathy in trauma and surgery. Dosing of PCC is guided by the prothrombin time, which only reflects the onset of thrombin generation, but does not account for variations in intrinsic pathway coagulation factors, including factor IX (FIX). We hypothesised that FIX contained in PCC could strongly influence thrombin generation patterns. Methods: Pooled normal, FIX-deficient, and warfarinised plasma were used to analyse the effects of FIX contained in PCC. PCC was evaluated at final concentrations of 0.2 and 0.4 IU ml À1 in FIX-deficient and normal plasma, and at 0.6 IU ml À1 in
Editor's key points
Prothrombin complex concentrate (PCC) dosing is usually guided by assessment of prothrombin time results. The contribution of individual coagulation factors, such as factor IX (FIX) and FVIII is, however, masked by a high tissue factor concentration in this test. Under low tissue factor concentrations, this study shows that FIX, together with FVIII, influences PCCinduced thrombin generation, which could have clinical relevance in warfarinised patients. These findings support development of a tissue factoractivated coagulation test that reflects overall thrombin generation.
Management of coagulopathy can be a major challenge during complex cardiovascular surgery and after severe trauma. 1, 2 Plasma-derived and recombinant factor concentrates are increasingly important therapeutic options in these settings. Prothrombin complex concentrate (PCC) is a lyophilised coagulation factor mixture containing prothrombin [factor II (FII)], FVII, FIX, and FX, which has been recently approved for acute warfarin reversal in the USA. 3, 5 The dosing of PCC is based on the amount of FIX per body weight (IU kg
À1
), and therapeutic responses are determined by correction of prothrombin time (PT) or international normalised ratio (INR). 3, 5 However, tissue factor-triggered PT/INR are unaffected by FIX, and it is possible that procoagulant activity of PCC is not fully appreciated in these results. While PT and activated partial thromboplastin time (aPTT) reflect the onset of fibrin gel formation, the propagation phase of thrombin generation, where thrombin mediates the feedback-activation of multiple factors, cannot be detected by either test. The thrombin generation assay is more sensitive than aPTT to the changes in thrombin generation because of antithrombin (AT)-mediated inhibitions of activated FX (FXa) and thrombin. 6, 7 FVIII is a crucial cofactor of FIX in the formation of tenase (FIXaeFVIIIa), which propagates FX activation and subsequent thrombin generation through the intrinsic pathway. It is important to consider the contribution of intrinsic tenase to thrombin generation because elevated FVIII or FIX concentrations have been associated with prothrombotic tendency under certain conditions including advanced age 8 and presence of a ventricular assist device. 9 It was hypothesised that the interaction between FVIII and PCCderived FIX plays a pivotal role in augmenting thrombin generation in dilutional coagulopathy. The aim of the present study is to quantify the PCC-mediated augmentation of intrinsic tenase and thrombin generation in normal and FIX-deficient plasma samples with and without haemodilution.
Methods
All parts of the study were conducted under institutional review board approval at the University of Maryland, Baltimore, MD, USA. Normal pooled plasma, FIX deficient (haemophilia B) plasma, and warfarin-treated plasma derived from healthy volunteers or de-identified clinical patients were obtained from George King Biomedical, Overland Park, KS, USA. The range of the INR in warfarin treated plasma was 2.3e2.9 (median, 2.6). All plasma samples were stored at e80 C, and then warmed to 37 C in a water bath immediately before analysis. Plasma samples underwent no more than one freeze-thaw cycle.
Thrombin generation assays were performed using a calibrated automated thrombography technique as originally described by Hemker and colleagues. 10 Briefly, 20 ml of tissue factor activator (final concentration, 2 pM) was added, followed by 80 ml of plasma to the wells of a microtitre plate (Thermo Labsystems, Franklin, MA, USA). Tissue factor concentrations of 1e2 pM are suitable for the evaluation of FIX activity, FVIII activity, or both. 11e13 The plate was incubated for 10 min at 37 C. A mixture of 20 ml (in total) of fluorogenic substrate/CaCl 2 (Diagnostica Stago, Parsippany, NJ, USA) and HEPTEM reagent (TEM Innovations, Munich, Germany) was then automatically dispensed into each well to start the reaction. The latter was added to neutralise the in vitro effects of heparin contained in commercial PCCs. 14 15 representing the procoagulant phase (ETPp) before the peak of thrombin generation, and inhibitory phase (ETPi) after the peak when AT-mediated inhibitions of FXa and thrombin take place. Briefly, this was calculated by integrating the area under the curve up to the peak to give ETPp, and then subtracting that from the total to give ETPi. Thrombin generation patterns under moderate (40%) haemodilution were modelled by mixing each plasma sample with saline (6:4 vol/vol). These conditions were selected to match typical patterns of haemodilution observed after moderately complex non-cardiac and cardiac operations. 17, 18 The 40% dilution lowers procoagulant factor concentrations, but it also affects AT activity, modulating therapeutic responses to PCC. 15, 19 For all experiments, phosphate buffered saline was added to control samples to account for the added volume of factor concentrate, which was less than 1% of the total plasma volume. All testing conditions are listed in Supplementary Table S1 .
Contributions of intrinsic tenase to thrombin generation

Statistical analysis
Assuming a mean (standard deviation) peak thrombin generation of 79.0 (6.0) nM in FIX-deficient plasma samples, an a of 0.05, and 80% power, previous studies indicate that at least five samples would be sufficient to show a 15% change in peak thrombin generation with the addition of PCC, FVIII, or both. 11, 12 Thrombin generation data were summarised as the median value (interquartile range). Thrombin generation parameters (lag time, peak thrombin, and ETPs) were compared across treatment groups using Friedman's test and Dunn's multiple comparison test. Friedman's test was selected because the data were non-
parametric. An a of 0.0033 was considered statistically significant after accounting for multiple comparisons. All statistical procedures were performed using Graphpad Prism 6 (GraphPad Software, La Jolla, CA, USA).
Results
Amplification of thrombin generation by intrinsic tenase
Compared with normal plasma, thrombin generation patterns in FIX-deficient plasma triggered with 2 pM tissue factor were characterised by reduced peak thrombin generation and ETP values, but normal lag time (Table 1 ). Adding 1.5 IU ml À1 of FVIII to normal plasma significantly increased the peak thrombin generation but induced minimal changes in FIXdeficient plasma. FIX derived from PCC increased the peak and ETP values in FIX-deficient plasma in a concentration dependent manner, while lag time values were marginally shortened ( Table 1 ). The combination of FVIII and PCC resulted in significant increases in peak thrombin generation relative to the addition of each agent in isolation. Notably, the peak thrombin generation concentration in FIX-deficient plasma fell short of normal plasma concentrations after adding 0.2e0.4 IU ml À1 of PCC but was successfully normalised after combining PCC and FVIII. Overall changes observed after 40% dilution were shorter lag time, and higher peak and ETP values compared with nondiluted plasma (Table 2 ). These paradoxical changes are partly explained by the dilution of AT, which slows down the inhibition of procoagulant proteases. 20 Similar to the undiluted conditions, PCC enhanced peak thrombin generation and ETP values in both normal and FIX-deficient plasma. Simultaneous additions of PCC and FVIII lead to more extensive increases in peak thrombin generation and ETP values relative to individual addition of each agent. In contrast to normal and FIX-deficient plasma samples, thrombin generation patterns in warfarinised plasma were characterised by prolonged lag time, and reduced peak and ETP values (Table 3 ). The addition of 1.5 IU ml À1 of FVIII did not result in any significant changes, but the addition of 0.6 IU ml À1 of PCC with or without FVIII reduced lag times, and enhanced peak and ETP values. In the presence of 40% dilution, the combination of PCC and FVIII resulted in significantly higher peak and ETP values compared with the addition of PCC by itself to undiluted warfarinised plasma (Table 3) .
Procoagulant and anticoagulant phases of endogenous thrombin potential
Incremental changes to peak thrombin generation and ETP can be attributed to either the procoagulant (ETPp) or anticoagulant (ETPi) phase, 15 and thus respective changes in ETPp and ETPi were assessed (median, inter-quartile range). In normal plasma, ETPp and ETPi were 443.5 (403.4e461.5) nMÂmin, and 670.3 (555.1e745.9) nMÂmin, respectively. After 40% dilution, a non-significant decrease in ETPp and a non-significant increase in ETPi compared with pre-dilution samples were observed (Fig. 1) . Untreated diluted FIX-deficient plasma values remained lower than diluted normal plasma values. In diluted FIXdeficient plasma, only the addition of both 0.4 IU ml À1 PCC and FVIII resulted in significant differences from the untreated diluted FIX-deficient plasma ETPp values. However, the increases observed in ETPi were much larger (Fig. 1) . In undiluted warfarinised plasma, ETPp and ETPi values were significantly lower than normal plasma values. The addition of FVIII, 40% dilution, or both, caused a statistically significant increase in ETPp relative to the undiluted warfarinised plasma (Fig. 2) . The changes in ETPi after FVIII addition, 40% dilution, or both, were more pronounced than those in ETPp, particularly after the dilution (Fig. 2) .
Discussion
Measurement of PT/INR is the current standard in dose calculation and monitoring the therapeutic response of PCC. 3, 5, 21, 22 However, PT/INR are triggered by tissue factor in 13 These clinical data corroborate our results in which 40% recovery (0.4 IU ml À1 ) of PCC in FIXdeficient plasma incompletely restored peak thrombin generation to the normal concentration. In our present study, thrombin generation in FIX-deficient plasma triggered by 2 pM tissue factor was decreased compared with normal plasma, but incrementally improved with 0.2 and 0.4 IU ml À1 of FIX derived from PCC. This obviously underlies the historical use of PCC in haemophilia B (FIX deficiency). Elevated FVIII concentrations seem to further enhance thrombin generation peak and ETP toward normal concentrations in concert with added FIX (Table 1) . In contrast to PT/INR, thrombin generation triggered by low-dose tissue factor leads to limited amounts of FXa and thrombin via extrinsic tenase (FVIIa/tissue factor). 26 Initially formed FXa and thrombin are quickly inhibited by tissue factor pathway inhibitor, AT, or both, and thus FIX is a key regulator of sustained thrombin generation. FIX is also activated by FVIIa/ tissue factor, and AT-mediated FIXa inhibition is slower than FXa inhibition. 27 Once FIXa is incorporated into the tenase complex with thrombin-activated FVIIIa, AT is no longer effective in inhibiting FIXa. 28 Taken together, these data suggest that FIX derived from PCC strongly enhances low-dose tissue factor-triggered thrombin generation in the presence of elevated FVIII activity. We further explored the augmentation of thrombin generation by intrinsic tenase in the presence of dilutional AT deficiency. This experiment is clinically pertinent because PCC is increasingly used in post-trauma or perioperative dilutional coagulopathy in which procoagulant and anticoagulant proteins are both affected. 19, 29 Relative shortening of lag time, and increases in peak thrombin generation and ETP were observed after 40% dilution compared with non-diluted controls (Tables 1  and 2 ). These changes are attributed to dilution-induced low AT activity, resulting in slower inhibitions of FXa and thrombin. 20 Although PT/INR triggered by nanomolar-range tissue factor is ); e indicates no treatment with FVIII or PCC. A P value of <0.0033 was considered statistically significant after accounting for multiple comparisons. *Statistically significant difference from untreated warfarin plasma; y statistically significant difference from warfarin plasma spiked with FVIII; z statistically significant difference from warfarin plasma with PCC 0.6 IU ml À1 . ETP, endogenous thrombin potential; FVIII, factor VIII; PCC, prothrombin complex concentrate. insensitive to low AT activity after haemodilution, 18.29 thrombin generation assay triggered by low-dose tissue factor ( 5 pM) is affected by AT concentrations, and preserved thrombin generation patterns have been reported in neonates 24 and patients with end-stage liver disease. 15, 25 Extensive increases in the post-peak ETP (ETPi) in the presence of FIX and high FVIII seem to indicate that intrinsic tenase (FIXa/FVIIIa) rather than the initial formation of extrinsic tenase (tissue factor/FVIIa) affect thrombin generation patterns after dilution (Fig. 1) . Even in the presence of deficient plasma (40% dilution using normal saline) were compared across treatments groups using Friedman's test and Dunn's multiple comparison test. Treatment groups were compared against untreated diluted FIX deficient plasma (left column). Normal plasma represents FIX-containing plasma under 40% dilution with normal saline. A P value of <0.0033 was considered statistically significant after accounting for multiple comparisons. Abbreviations: IU: international unit; nM: nanomolar; min: minute; ETPp: procoagulant endogenous thrombin potential; ETPi: inhibitory endogenous thrombin potential. z Statistically significant difference from untreated plasma ETPi. x Statistically significant difference from untreated plasma ETPp.
Fig 2.
Effects of factor VIII (FVIII, 1.5 IU ml À1 ) and prothrombin complex concentrate (PCC) additions on ETPp and ETPi in warfarinized plasma were compared across treatments groups using Friedman's test and Dunn's multiple comparison test. Treatment groups were compared against untreated warfarinized plasma (left column). A P value of <0.0033 was considered statistically significant after accounting for multiple comparisons. Abbreviations: IU: international unit; nM: nanomolar; min: minute; ETPp: procoagulant endogenous thrombin potential; ETPi: inhibitory endogenous thrombin potential; Dil.: 40% dilution using normal saline. y Statistically significant difference from untreated plasma ETPi. # Statistically significant difference from untreated plasma ETPp.
normal AT concentrations, FIXa inhibition by AT is slower than FXa inhibition. 27 The therapeutic concentration of PCC (0.6 IU ml À1 ) that reverses warfarin anticoagulation (Table 3 ) also resulted in extensive increases in ETPi relative to ETPp after dilution (Fig. 2) . The largest increase of ETPi was observed in the presence of both PCC and FVIII. The lag time was not found to be particularly useful to detect changes induced by the combination of PCC and FVIII. Taken together, FIX derived from PCC plays a pivotal role in regulating the extent of thrombin generation in the presence of FVIII. The activity of intrinsic tenase (FIXa/FVIIIa) is particularly augmented in the presence of low AT activity because of enhanced feedback activations of FVIIIa (a cofactor of FIX) and FXIa (Fig. 3) .
There Acute warfarin reversal with PCC for surgical and invasive procedures was associated with a 7% incidence of thromboembolic complications. 5 However, the risk of thrombosis may be greater with off-label PCC use, particularly in cardiac surgery, as other haemostatic agents are often utilised concurrently, haemodilution is common, and FVIII concentrations are elevated after cardiopulmonary bypass. 39 Thus, perioperative PCC dosing scheme needs to be improved beyond PT/INR and weight-based nomograms. 20, 21 There are several limitations to our study. First, the findings are limited to in vitro plasma models excluding rheological elements of coagulation. However, elevated ETP in plateletpoor plasma has been associated with thromboembolic risks. 40, 41 Extremely high ETPs were observed after 50 IU kg
À1
of PCC in the porcine dilution model with 41% of baseline AT activity, which resulted in elevated markers of intravascular coagulation (elevated thrombin-AT complex), and macroscopic thromboemboli (e.g. lung and liver) in the post-mortem. 42 Second, there is wide variability in the contents of commercial PCC products in the balance of procoagulant and anticoagulant proteins. 43 PCC products indicated for warfarin reversal contain therapeutic amounts of protein C and protein S. Although not performed in our study, addition of thrombomodulin to test samples allows evaluation of protein C activation during thrombin generation, 41 and this deserves a further consideration as PCC provides both protein C and protein S. Lastly, this study was exploratory in nature, and the contribution of FIX from PCC to thrombin generation needs to be validated in a larger clinical setting.
In conclusion, our data suggest that FIX derived from PCC contributes to enhanced thrombin generation in the presence of high FVIII. A slower inhibition of thrombin generation in the presence of low AT after dilution cautions the use of escalating PCC doses based on a prolonged PT/INR. This hypothesis needs to be explored in adequately powered studies of perioperative patients in whom PCC is administered in the setting of dilutional coagulopathy and elevated FVIII concentrations. Handling editor: C. Boer
